Anderson ES, et al. - In view of increasing numbers of melanoma patients on anti-PD-1 therapy, authors determined the safety and initial response of brain metastases treated with concurrent pembrolizumab and radiation therapy. In patients with metastatic melanoma, concurrent pembrolizumab with brain radiation therapy (RT) appeared safe. Stereotactic radiosurgery (SRS), in particular, markedly reduced the size of brain metastases at the time of first follow-up MRI. These results compare favorably to SRS in combination with ipilimumab and SRS without concurrent immunotherapy.